Tiny implant could track oxygen in legs of PAD patients

NCT ID NCT04514861

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new wireless sensor that is injected under the skin to measure oxygen levels in the legs of people with peripheral artery disease (PAD). The sensor tracks how oxygen changes when blood flow is altered by a pressure cuff or changing position. Researchers want to see if this device works as well as current methods. Fifty-three adults with stable PAD will be followed for 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 53 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2020

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: A suitable candidate must meet the following criteria: * Male or female must be ≥ 18 years of age * Diagnosed with PAD, stable at time of enrollment, and may include prior stable lower extremity revascularization * Has been informed of the nature of the study, agrees to its provisions, and has signed the informed consent form prior to any study related procedure * Should plan to be available for all safety follow-up examinations at the investigational site * Is aware that the Lumee™ Oxygen hydrogels are intended to stay in the tissue indefinitely * Is aware that photos of injection sites and wound site will be taken, and videos may be recorded Exclusion Criteria: A candidate will be excluded from the study if any of the following criteria are met: * PAD of Rutherford Classification 5 or 6 at time of enrollment * Subject has an active infection * Subject has an open wound on limb included in study * Known history of keloids, excessive fibrosis during wound healing * Known allergies to Lumee™ Oxygen hydrogel components, local anesthetic agents, suture materials, or severe skin allergies to adhesives * Any skin or musculoskeletal condition or deformity limiting injection of the Lumee™ Oxygen hydrogel or preventing subsequent attachments of the Lumee™ Patch system * Any skin modification in the area of injection that would potentially influence device performance (for example tattoos or scars) * Previous amputation proximal to the digital level on the limb included in the study * Significant venous insufficiency resulting in swelling of the lower leg, ankle or foot or chronic venous stasis changes (CEAP clinical score ≥ 3) * Any condition that at the discretion of the investigator, physician or designee will impact the safety of the subject or the scientific integrity of the trial * Female subjects of childbearing capacity (not surgically sterile or menopausal for ≥ 1 year) * Participation in another clinical study, that would potentially interfere with the participation in this study * Subject requires dialysis * Subject is immunocompromised * Subject has incompressible arteries tested by occlusion test in the arm * Inability to obtain consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Peripheral artery disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • San Francisco General Hospital

    San Francisco, California, 94110, United States

  • San Francisco Veterans Affairs Medical Center (SFVAMC)

    San Francisco, California, 94121, United States

  • UCSF Medical Center

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.